EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review

Xabier Aizpurua-Arruti iD, Estíbaliz Goyenechea iD, Arantxa Isla iD, Ainhoa Oñatibia-Astibia iD, Amaia Malet-Larrea iD, Miguel Ángel Gastelurrutia iD, María Ángeles Solinís iD, Ana Del Pozo-Rodriguez iD

Pharmacoepidemiology and Drug Safety · 2025-09 · 34 (9)

DOI: 10.1002/pds.70201 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 15.08.2025. Verfasst von Xabier Aizpurua-Arruti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Official Pharmacist Association of Gipuzkoa, Donostia, San Sebastián, Spain. Hauptthemen laut MEDLINE: Pharmacovigilance, Pharmacists, Adverse Drug Reaction Reporting Systems, Professional Role. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Education of the Basque Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pharmacovigilance plays a critical role in ensuring the safety of medicinal products, particularly those under additional monitoring (AM). The European Union (EU) implemented AM in 2012 to enhance post‐marketing surveillance. However, its impact on adverse drug reaction (ADR) reporting and pharmacists' role remains insufficiently explored. This scoping review examines the influence of AM label on ADR reporting management, and pharmacists' awareness and involvement in AM medicines.

Methods

A systematic search across four scientific databases (Web of Science, Scopus, Science Direct, and PubMed) and gray literature sources, covering studies published between 2012 and 2024 in the EU, identified 17 relevant studies according to eligibility criteria: AM labeling's impact on pharmacovigilance in the EU. Relevant data (title, year of publication, country, field, design, objective, results) and relation with research questions were charted.

Results

AM label alone does not significantly increase ADR reporting rates. However, structured training programs and targeted interventions for healthcare professionals (HCPs), particularly pharmacists, lead to improved ADR reporting and patient safety outcomes. Pharmacists exhibit the highest awareness of AM among HCPs but often underutilize their role in ADR reporting. Different studies demonstrated that pharmacist‐led interventions significantly increased ADR notifications. Education campaigns, standardized reporting protocols, and enhanced integration of AM into clinical practice can strengthen AM pharmacovigilance efforts.

Conclusions

This review highlights the need to implement structured AM training programs and develop systematic evaluation frameworks to assess the effectiveness of AM labeling in improving pharmacovigilance practices. Further research is required to optimize AM strategies and reinforce pharmacists' role in post‐marketing drug safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilancePharmacistsAdverse Drug Reaction Reporting SystemsProfessional RoleDrug-Related Side Effects and Adverse ReactionsHumansEuropean UnionDrug LabelingDrug Monitoring

Stichwörter der Autor:innen

additional monitoringadverse drug reactionpharmacovigilancepharmacysafety

Autor:innen und Institutionen

  • Official Pharmacist Association of Gipuzkoa, Donostia, San Sebastián, Spain.
  • Pharmacy Practice Research Group, PharmaNanoGene Group, Faculty of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
  • Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy, Vitoria-Gasteiz, Spain.
  • Pharmaceutical Care Research Group, Faculty of Pharmacy, University of Granada, Granada, Spain.

ORCID-Profile: Xabier Aizpurua-Arruti, Estíbaliz Goyenechea, Arantxa Isla, Ainhoa Oñatibia-Astibia, Amaia Malet-Larrea, Miguel Ángel Gastelurrutia, María Ángeles Solinís, Ana Del Pozo-Rodriguez

Förderung

  • Department of Education of the Basque Government

Zitieren

APA

Aizpurua-Arruti, X., Goyenechea, E., Isla, A., Oñatibia-Astibia, A., Malet-Larrea, A., Gastelurrutia, M. Á., Solinís, M. Á., & Del Pozo-Rodriguez, A. (2025). Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review. Pharmacoepidemiology and Drug Safety, 34(9). https://doi.org/10.1002/pds.70201

Vancouver

Aizpurua-Arruti X, Goyenechea E, Isla A, Oñatibia-Astibia A, Malet-Larrea A, Gastelurrutia MÁ, et al. Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review. Pharmacoepidemiology and Drug Safety. 2025;34(9). doi:10.1002/pds.70201

BibTeX
@article{AizpuruaArruti2025,
  author = {Aizpurua-Arruti, Xabier and Goyenechea, Estíbaliz and Isla, Arantxa and Oñatibia-Astibia, Ainhoa and Malet-Larrea, Amaia and Gastelurrutia, Miguel Ángel and Solinís, María Ángeles and Del Pozo-Rodriguez, Ana},
  title = {Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  volume = {34},
  number = {9},
  doi = {10.1002/pds.70201}
}
Kostenlos starten →